The hyperactivity of SREBF1 leads to lipid accumulation and atherosclerosis, increasing AMI risk.[31] It is also closely linked to metabolic syndrome, a major risk factor for AMI.[32] Chunjuan Chen showed that the SIRT1/NF-κB/sCD40L axis is elevated in AMI patients, with SIRT1 levels positively correlating with cardiac troponin T.[33] SIRT1, a NAD+ dependent deacetylase, regulates cellular metabolism, aging, and stress responses. Here, SREBF1 is linked to metabolic syndrome.